Project Grant R01AG095248
Award Date 1/1/26
Completion Date 12/31/30
Dollars Obligated $683K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
University City, MO 63130, USA
Similar Awards
- This $4.49 million project grant from the National Institutes of Health's National Institute on Aging will fund research at The Washington University to investigate the relationship between amyloid plaque deposition, cellular metabolic dysfunction, and functional brain organization in Alzheimer's disease (AD) mice models. Over three years, the researchers will use multi-photon fluorescence lifetime imaging microscopy, multi-parametric photoacoustic microscopy, and wide-field optical imaging to...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,851,569.00 in funding to The Washington University to conduct research on how early brain development informs later neurodegeneration, with a focus on Alzheimer's disease. The project aims to determine if regions of the brain with high plasticity during early development are more susceptible to pathological changes later in life, and if adverse developmental conditions have...
- This $500,000 Project Grant was awarded on September 15, 2024 by the National Institute on Aging (CFDA 93.866 Aging Research program) to Neucyte Inc., a minority-owned small business specializing in advanced biomedical research and development. The funding will support the development of a miniaturized "mini-brain" microphysiological system (MPS) platform using Alzheimer's disease (AD) patient-derived cells. The goal is to create a scalable, reproducible in vitro brain model that can...
- This federal Project Grant award of $716,579, awarded by the National Institute on Aging (CFDA 93.866 - Aging Research), supports research to investigate the role of microglia, the immune cells of the brain, in the progression of Alzheimer's disease (AD). Specifically, the research aims to genetically dissect the relationships between different activated states of microglia and their involvement in complement-mediated synapse loss, which is a key neurobiological driver of cognitive decline in...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $398,046 to the Palo Alto Veterans Institute for Research (PAVIR) to systematically test the combined effects of anti-amyloid treatment and brain stimulation for treating mild cognitive impairment (MCI) and Alzheimer's disease (AD) in a mouse model. The research aims to assess the biochemical response, memory improvements, and electrocorticography (ECoG) changes resulting from the combined...
- This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), provides $2,316,710 to The Regents of the University of California, Berkeley to develop magnetogenetic techniques for manipulating the activity of specific brain cell types implicated in the onset and progression of Alzheimer's disease (AD). The objectives are to use enhanced adeno-associated virus (AAV) vectors and the FERIC magnetogenetic tool to non-invasively...
- The Project Grant award titled "ENHANCER-AAVS TO MONITOR AND RESTORE CELL-TYPE SELECTIVE INHIBITORY DEFICITS AND CIRCUIT DYSFUNCTION IN HUMANIZED ALZHEIMER'S DISEASE MODELS" was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The $1,459,072.00 award, granted to the J. David Gladstone Institutes, aims to monitor and manipulate inhibitory interneuron cell populations in mouse models to assess their contribution to...
- The National Institute on Aging (NIA), under the Federal Aging Research program (CFDA 93.866), awarded a $245,148 project grant to Eyenexo LLC to develop an automated rodent behavior testing system for non-invasively assessing early-stage Alzheimer's disease (AD). The project aims to develop a behavior biomarker that can differentiate AD from normal aging by studying defensive behaviors triggered by looming stimuli, which are linked to early AD pathology in the midbrain region. The 2-year...
- This federal Project Grant award for $1,249,957.00 was provided by the National Institute on Aging (NIA), which administers the Aging Research federal grant program (CFDA 93.866). The funding will support preclinical and IND-enabling studies for a small molecule drug candidate that is designed to be disease-modifying, low-cost, and require only 6 subcutaneous injections per year for the treatment of Alzheimer's disease. The goal is to develop a new therapeutic that can improve the clearance of...
- This Project Grant award of $108,512.00 was provided by the National Institute on Aging (CFDA 93.866 - Aging Research) to Oregon Health & Science University (OHSU) on March 6, 2025. The goal of this project is to study the mechanisms underlying neurovascular coupling (NVC) impairment and its contribution to cognitive decline and Alzheimer's disease (AD)-related pathology. Specifically, the researchers will investigate how ischemia-induced increases in the vasoconstrictor endothelin-1...